FDA批准leronlimab的CyoDyn II期研究

2024-11-04 23:22

CytoDyn (OTCQB:CYDY) said the FDA has cleared a Phase 2 study of its drug leronlimab for the treatment of relapsed/refractory microsatellite stable colorectal cancer.
Patient enrollment for the study will begin in early 2025. The study will be conducted with Syneos Health.
“This milestone reflects the continued positive development of the company’s improved relationship with the FDA,” CytoDyn (OTCQB:CYDY) said in a statement.
Shares of CytoDyn (OTCQB:CYDY) rallied in February after the company announced the FDA had lifted a clinical hold on leronlimab.

More on CytoDyn